Mondobiotech primarily focuses on bioactive peptides of human origin, which are re-directed to be used for the treatment of rare and neglected diseases (dry search). Mondobiotech believes that peptides offer better safety profiles compared to most other classes of molecular entities. As a consequence, Mondobiotech expects the risk of failure of development associated with toxicity and other adverse effects to be significantly lower than in the case of non-human originated products. The Peptides' cell interactions, communications and behaviors within the organisms have been selected for millions of years for efficacy and safety and represent the nature's compromise for said features. Almost every human being has been exposed to a majority of those peptides and the human immune system therefore accepts them as "its own". Many peptides are main constituents of human milk – a nutrient necessary and sufficient to provide protection and all elements for the growth of babies. Moreover, a significant number of Mondobiotech's peptides has already been tested in clinical trials by pharmaceutical researchers and for other indications.
The combination of
- Mondobiotech’s dry search and expertise on peptides,
- the results of the continuous interaction with Mondobiotech’s Community and
- Mondobiotech’s know how to bring a hypothesis to a development project
constitute Mondobiotech’s products offered for licensing. The licensing documentation includes 6 DVDs, each addressing a specific area of expertise and specifically the following areas: peptide, disease, drug development, intellectual property and legal, financial and services which Mondobiotech is available to provide to its licensees.